Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07333885
NA

Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)

Sponsor: Phynova Group Ltd

View on ClinicalTrials.gov

Summary

The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.

Official title: The Impact of Reducose® on Symptoms of Perimenopause and Glycemic Response: a Randomized Controlled Trial

Key Details

Gender

FEMALE

Age Range

40 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-12-12

Completion Date

2026-08

Last Updated

2026-01-12

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

Reducose® (Mulberry leaf extract)

Reducose® proprietary mulberry leaf extract, 250mg, 2/day with meals

DIETARY_SUPPLEMENT

Placebo

Placebo matching capsules, Microcrystalline Cellulose

Locations (1)

People Science

Los Angeles, California, United States